Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy with Aprepitant/Fosaprepitant in Patients with Colorectal Cancer Receiving Oxaliplatin-based chemotherapy - Study of Aprepitant/Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Colorectal Cancer Patients (SENRI)

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group0 个研究点目标入组 413 人开始时间: 2011年4月14日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 413

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015 Jul;51(10):1274-82. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol 2017;22(1):88-95.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 48 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is unable to be administered dexamethasone for 3 days due to associated illnesses such as out-of-control diabetes mellitus 6) Patient is pregnant or lactating woman, and woman who plans to become pregnant 7) Patient is receiving treatment with pimozide 8) Patient is judged inappropriate by the investigator as subject for this study

研究者

发起方

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group

相似试验

撤回

1 期

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCColorectal Cancer

NCT03169777ImmunityBio, Inc.

Unknown

2 期

Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal CancerMetastatic Colorectal Cancer

NCT03132025Yanqiao Zhang40

已完成

2 期

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy FailureLiver MetastasesColorectal Cancer

NCT01348412Centre Georges Francois Leclerc31

Unknown

2 期

Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal CancerNeoadjuvant TherapyColorectal Cancer

NCT03377842Sichuan Provincial People's Hospital100

已完成

3 期

Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal CancerLength of StayComplicationsAdverse Drug EventQuality of LifeHospital Costs

NCT01080547Zhejiang University374